OBJECTIVE: The goal of our study was to investigate the inverse correlation between number of genetic aberrations and malignancy grade in ependymal tumors at the ploidy level. METHODS: we examined seven myxopapillary ependymomas (mpEs) (WHO grade I), 28 spinal and cerebral ependymomas (Es) (WHO grade II), and 18 cerebral anaplastic ependymomas (aEs) (WHO grade III) using image DNA cytometry. The ploidy status was correlated with clinicopathological characteristics and with the results obtained by comparative genomic hybridization (CGH) analysis that we performed in about half of these tumors. RESULTS: mpEs were exclusively located in the spinal cord and aEs in the cerebrum only, whereas Es were located in both the spinal cord and brain. We found aneuploidy or tetraploidy to be common in the group of mpEs (6 out of 7) and much less frequent in Es (6 out of 28) and aEs (4 out of 18). Three-year postoperative survival was 100% for mpEs, 100% for spinal Es, 92% for cerebral Es, and 33% for aEs. Our CGH results in a selection of these tumors revealed the highest number of genetic aberrations in the mpEs (average 16; n = 2), a lower number in Es (average 12; n = 11) and the lowest number in aEs (average 5; n = 6). Interestingly, in the group of Es and aEs, a high number of genetic aberrations as detected by CGH was not correlated with aneuploidy or tetraploidy. Three patients, all with mpEs had local seeding. CONCLUSION: These results underline that mpEs are distinctly different from Es and aEs at the genetic level and that extensive genomic alterations and aneuploidy in ependymal tumors are not in itself an indicator of malignant behavior.
OBJECTIVE: The goal of our study was to investigate the inverse correlation between number of genetic aberrations and malignancy grade in ependymal tumors at the ploidy level. METHODS: we examined seven myxopapillary ependymomas (mpEs) (WHO grade I), 28 spinal and cerebral ependymomas (Es) (WHO grade II), and 18 cerebral anaplastic ependymomas (aEs) (WHO grade III) using image DNA cytometry. The ploidy status was correlated with clinicopathological characteristics and with the results obtained by comparative genomic hybridization (CGH) analysis that we performed in about half of these tumors. RESULTS: mpEs were exclusively located in the spinal cord and aEs in the cerebrum only, whereas Es were located in both the spinal cord and brain. We found aneuploidy or tetraploidy to be common in the group of mpEs (6 out of 7) and much less frequent in Es (6 out of 28) and aEs (4 out of 18). Three-year postoperative survival was 100% for mpEs, 100% for spinal Es, 92% for cerebral Es, and 33% for aEs. Our CGH results in a selection of these tumors revealed the highest number of genetic aberrations in the mpEs (average 16; n = 2), a lower number in Es (average 12; n = 11) and the lowest number in aEs (average 5; n = 6). Interestingly, in the group of Es and aEs, a high number of genetic aberrations as detected by CGH was not correlated with aneuploidy or tetraploidy. Three patients, all with mpEs had local seeding. CONCLUSION: These results underline that mpEs are distinctly different from Es and aEs at the genetic level and that extensive genomic alterations and aneuploidy in ependymal tumors are not in itself an indicator of malignant behavior.
Authors: D A Reardon; R E Entrekin; J Sublett; S Ragsdale; H Li; J Boyett; J L Kepner; A T Look Journal: Genes Chromosomes Cancer Date: 1999-03 Impact factor: 5.006
Authors: S Scheil; S Brüderlein; M Eicker; J Herms; C Herold-Mende; H H Steiner; T F Barth; P Möller Journal: Brain Pathol Date: 2001-04 Impact factor: 6.508
Authors: Judith W M Jeuken; Sandra H E Sprenger; Job Gilhuis; Hans L J M Teepen; Andre J Grotenhuis; Pieter Wesseling Journal: J Pathol Date: 2002-06 Impact factor: 7.996
Authors: M Carter; J Nicholson; F Ross; J Crolla; R Allibone; V Balaji; R Perry; D Walker; R Gilbertson; D W Ellison Journal: Br J Cancer Date: 2002-03-18 Impact factor: 7.640
Authors: Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters Journal: Neuro Oncol Date: 2008-08-01 Impact factor: 12.300
Authors: V Rand; E Prebble; L Ridley; M Howard; W Wei; M-A Brundler; B E Fee; G J Riggins; B Coyle; R G Grundy Journal: Br J Cancer Date: 2008-09-09 Impact factor: 7.640